Our Products

OpioidStatement

  • Can cause addiction contains opioid
  • The Butec 5μg/h transdermal patch should be used as the
    initial dose3,4
  • No dose adjustment of Butec is required in the elderly3,4
  • No special dose adjustment is required in patients with
    renal impairment3,4

Prescribing Information – Butec 15 microgram/hour transdermal patch.

 

Prescribing Information – Butec 5, 10 and 20 microgram/hour transdermal patch

Patches are not shown at actual size.

Butec patches have a list price 55% lower than BuTrans® (buprenorphine) patches1

Patch Strength & Pack Size Butec List Price1 BuTrans List Price1 NHS Saving when Butec Prescribed
5 μg/h x 4 qdem-butec-patch-5ug £7.92 £17.60 £9.68
10 μg/h x 4 qdem-butec-patch-10ug £14.20 £31.55 £17.35
15 μg/h x 4 £22.12 £49.15 £27.03
20 μg/h x 4 qdem-butec-patch-20ug £25.86 £57.46 £31.60
Save vs. BuTrans every time you Rx Butec. For every 1000 patients switched from BuTrans 10μg/h to Butec 10μg/h you can save £225,550 over 12 months1

Patches are not shown at actual size.

Butec

Identical formulation5,6

  • Butec patches are category C branded generic buprenorphine patches with an identical formulation to BuTrans patches5,6

Identical strength and appearance5,6

  • Butec patches are available in the same strengths and have identical patch dimensions, colour and texture to BuTrans patches5,6

Identical manufacturing and supply chain5,6

  • Butec patches utilise the same manufacturing facility and supply chain as BuTrans patches5,6

Identical Indication to BuTrans Patches3,4,5,6

  • For the treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.3,4,5,6
  • Can cause addiction contains opioid
  • Prolonged release oxycodone7
  • 12-hourly administration7
  • Biphasic release for immediate and sustained pain relief7
  • Titrate (if needed) in increments of 25-50% until pain control is achieved7
  • Longtec tablets have the same appearance as OxyContin® (oxycodone) tablets and are colour-coded to indicate dose7,8

Prescribing Information – Longtec 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg and 120 mg prolonged release tablets

Longtec tablets have a list price 50% lower than OxyContin® tablets1

Tablet Dose Longtec List Price1 OxyContin List Price1 NHS Saving when Longtec Prescribed
5 mg x 28 £6.26 £12.52 £6.26
10 mg x 56 £12.52 £25.04 £12.52
15 mg x 56 £19.06 £38.12 £19.06
20 mg x 56 £25.04 £50.08 £25.04
30 mg x 56 £38.11 £76.23 £38.12
40 mg x 56 £50.09 £100.19 £50.10
60 mg x 56 £76.24 £152.49 £76.25
80 mg x 56 £100.19 £200.39 £100.20
120 mg x 56 £152.51 £305.02 £152.51
Save 50% vs. OxyContin every time you Rx Longtec

Tablets are not shown at actual size.

Prolonged release oxycodone hydrochloride

Treatment of severe pain requiring a strong opioid….

  • For the treatment of moderate to severe pain in patients with cancer and postoperative pain, and severe pain requiring the use of a strong opioid7
  • Range of strengths available, offering flexible dose titration according to patients’ needs7

Easy to switch

  • Longtec tablets are bioequivalent to OxyContin tablets8
  • Longtec tablets are the only branded generic to have the full OxyContin® dose range which includes the 120 mg strength7
  • Can cause addiction contains opioid
  • Immediate release oxycodone9
  • 4-6 hourly administration9
  • Starting dose is 5 mg, which can be carefully titrated as frequently as once-daily to achieve pain relief9
  • Shortec capsules have the same appearance as OxyNorm® (oxycodone) capsules10

Prescribing Information – Shortec 5, 10, 20 mg capsules

Shortec capsules have a list price 40% lower than OxyNorm® capsules.1

Capsule Dose Shortec List Price1 OxyNorm List Price1 NHS Saving when Shortec Prescribed
5 mg x 56 £6.86 £11.43 £4.57
10 mg x 56 £13.72 £22.86 £9.14
20 mg x 56 £27.43 £45.71 £18.28
Save 40% vs. OxyNorm every time you Rx Shortec

Tablets are not shown at actual size.

A like-for-like switch…

Identical benefits8,10

  • Identical Formulation
    Longtec and Shortec are branded generic oxycodones with an identical formulation to OxyContin and OxyNorm respectively8,10
  • Identical dosing and appearance
    Longtec tablets and Shortec capsules have the same dosing and appearance as OxyContin tablets and OxyNorm capsules8,10
  • Identical manufacturing and supply chain
    Longtec and Shortec utilise the same manufacturing facility and supply chain as OxyContin and OxyNorm8,10

It’s the name and price that are different

  • Longtec – Think long acting Oxycodone
  • Shortec – Think short acting Oxycodone
  • Can cause addiction contains opioid
  • Immediate release oxycodone11
  • 4-6 hourly administration11
  • For dose titration and break through pain11

Prescribing Information – Shortec liquid 1 mg/ml oral solution and concentrate 10 mg/ml oral solution

Shortec liquid and concentrate have a list price 15% lower than OxyNorm® (oxycodone) liquid and concentrate1

Liquid & Concentrate Dose Shortec List Price1 OxyNorm List Price1 NHS Savings when Shortec Prescribed
1 mg/ml x 250ml £8.25 £9.71 £1.46
10 mg/ml x 120ml £39.64 £46.63 £6.99
Save 15% vs. OxyNorm every time you Rx Shortec

  • Can cause addiction contains opioid
  • For I.V. and S.C. injection or infusion12,13

Prescribing Information – Shortec 10 mg/ml, solution for injection or infusion

 

Prescribing Information – Shortec 50 mg/ml, solution for injection or infusion

Shortec injection has a list price 15% lower than OxyNorm® (oxycodone) injection.1

Injection & Infusion Dose Shortec List Price1 OxyNorm List Price1 NHS Savings when Shortec Prescribed
10 mg/1 ml x 5 £6.80 £8.00 £1.20
20 mg/2 ml x 5 £13.60 £16.00 £2.40
50 mg/1 ml x 5 £59.59 £70.10 £10.51
Save 15% vs. OxyNorm every time you Rx Shortec

OpioidStatement
spacer
References

  1. MIMS online [Accessed April 2021] www.mims.co.uk
  2. Butec 5, 10 and 20 microgram/hour Transdermal Patch Summary of Product Characteristics [Accessed April 2021] https://www.medicines.org.uk/emc/product/1983
  3. Butec 15 microgram/hour Transdermal Patch Summary of Product Characteristics [Accessed April 2021] https://www.medicines.org.uk/emc/product/2384
  4. MHRA UKPAR Butec 5µg/h, 10µg/h and 20µg/h Transdermal Patch (buprenorphine) (PL40431/0024-0026). [Accessed April 2021]. https://mhraproducts4853.blob.core.windows.net/docs/fd912be7baccc1cd67597bfab3929f8f64dddaf6
  5. MHRA UKPAR Butec 15µg/h Transdermal Patch (buprenorphine) (PL 40431/0027). [Accessed April 2021]. https://mhraproducts4853.blob.core.windows.net/docs/0715ec1793eb156537b392998a0f4367b60152df
  6. Longtec Tablets Summary of Product Characteristics. [Accessed April 2021] www.medicines.org.uk/emc/product/7349
  7. MHRA UKPAR Longtec 5, 10, 20, 40 and 80mg film coated prolonged release tablets (PL 16950/0145-9). [Accessed April 2021]. https://products.mhra.gov.uk/search/?search=longtec&page=1
  8. Shortec Capsules Summary of Product Characteristics. [Accessed April 2021] https://www.medicines.org.uk/emc/product/5203
  9. MHRA UKPAR Shortec 5 mg, 10 mg and 20 mg hard capsules (PL 40431/0010–0012). [Accessed April 2021]. https://products.mhra.gov.uk/search/?search=shortec&page=1
  10. Shortec Liquid and Concentrate Summary of Product Characteristics. [Accessed April 2021] www.medicines.org.uk/emc/product/8103 
  11. Shortec 10 mg/ml solution for injection or infusion. Summary of Product Characteristics. [Accessed April 2021] https://www.medicines.org.uk/emc/product/2385
  12. Shortec 50 mg/ml solution for injection or infusion. Summary of Product Characteristics. [Accessed April 2021] https://www.medicines.org.uk/emc/product/2386
  13. O’Brien T et al. European Pain Federation position paper on appropriate use in chronic pain management. Eur J Pain 2017;21:3-19.
  14. Dowell D et al. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
  15. Faculty of Pain Medicine. Opioids Aware: A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain [Accessed April 2021] https://www.fpm.ac.uk/opioids-aware
  16. Rosenblum A et al. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16:405–16

Date of preparation June 2021 UK-PAIN-2100001